Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Average Recommendation of “Hold” by Brokerages

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has received a consensus rating of “Hold” from the seven ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $61.60.

SUPN has been the subject of several analyst reports. Bank of America started coverage on shares of Supernus Pharmaceuticals in a research note on Wednesday, October 29th. They issued a “buy” rating and a $65.00 target price for the company. Stifel Nicolaus lifted their price target on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research note on Friday, December 19th. Zacks Research lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 8th. Piper Sandler upgraded shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their target price for the company from $40.00 to $65.00 in a research report on Thursday, October 9th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Monday, December 29th.

Insider Activity

In related news, SVP Frank Mottola sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $50.41, for a total value of $1,008,200.00. Following the transaction, the senior vice president directly owned 15,496 shares in the company, valued at approximately $781,153.36. This represents a 56.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Padmanabh P. Bhatt sold 710 shares of the firm’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $44.44, for a total value of $31,552.40. Following the sale, the vice president directly owned 14,508 shares of the company’s stock, valued at approximately $644,735.52. This trade represents a 4.67% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 8.80% of the company’s stock.

Institutional Trading of Supernus Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Smartleaf Asset Management LLC raised its holdings in Supernus Pharmaceuticals by 30.8% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock valued at $54,000 after buying an additional 268 shares during the period. Arizona State Retirement System lifted its holdings in shares of Supernus Pharmaceuticals by 1.7% in the 3rd quarter. Arizona State Retirement System now owns 16,547 shares of the specialty pharmaceutical company’s stock worth $791,000 after acquiring an additional 277 shares during the last quarter. Hantz Financial Services Inc. boosted its position in shares of Supernus Pharmaceuticals by 81.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 281 shares during the period. Yousif Capital Management LLC increased its holdings in Supernus Pharmaceuticals by 1.5% in the 2nd quarter. Yousif Capital Management LLC now owns 21,032 shares of the specialty pharmaceutical company’s stock valued at $663,000 after purchasing an additional 305 shares during the last quarter. Finally, Amalgamated Bank increased its holdings in Supernus Pharmaceuticals by 2.0% in the 3rd quarter. Amalgamated Bank now owns 16,030 shares of the specialty pharmaceutical company’s stock valued at $766,000 after purchasing an additional 313 shares during the last quarter.

Supernus Pharmaceuticals Trading Down 0.1%

SUPN opened at $51.11 on Friday. The firm has a market capitalization of $2.93 billion, a PE ratio of -150.32, a P/E/G ratio of 0.50 and a beta of 0.67. The firm has a 50 day moving average of $47.93 and a two-hundred day moving average of $44.34. Supernus Pharmaceuticals has a 12-month low of $29.16 and a 12-month high of $57.65.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.82 by ($0.36). The company had revenue of $170.00 million for the quarter, compared to analyst estimates of $175.82 million. Supernus Pharmaceuticals had a positive return on equity of 11.51% and a negative net margin of 2.81%.Supernus Pharmaceuticals’s revenue for the quarter was up 9.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.69 earnings per share. As a group, analysts predict that Supernus Pharmaceuticals will post 2.38 EPS for the current fiscal year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.